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Epstein-Barr virus (EBV) is associated with nasopharyngeal carcinoma (NPC) tumorigenesis. However, the mechanism(s) 
connecting EBV infection and NPC remain unclear. Recently, a new class of EBV microRNAs (miRNAs) has been described. 
To determine how EBV miRNAs control the expression of host genes, and to understand their potential role in NPC tumor-
igenesis, we profiled the expression of 44 mature EBV miRNAs and potential host genes in NPC and non-tumor nasopharyn-
geal epithelial tissues. We found that 40 EBV miRNAs from the BART transcript were highly expressed in NPC. Analysis of 
potential BART miRNA target genes revealed that 3140 genes and several important pathways might be involved in the car-
cinogenesis of NPC. A total of 105 genes with potential EBV miRNA binding sites were significantly downregulated, sug-
gesting that EBV miRNAs may regulate these genes and contribute to NPC carcinogenesis. An EBV miRNA and host gene 
regulation network was generated to provide useful clues for validating of EBV miRNA functions in NPC tumorigenesis. 
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Epstein-Barr virus (EBV), also known as human herpesvi-
rus 4 (HHV-4), is a ubiquitous herpesvirus that asympto-
matically infects over 95% of the adult population world-
wide, and sporadically induces infectious mononucleosis. In 
the vast majority of cases, the virus establishes a lifelong 
latent infection without further complications. In certain 
circumstances, however, the virus has oncogenic potential. 
EBV is related to a broad spectrum of benign and malignant 
diseases, including tumors of B cell origin, such as Burkitt’s 
and Hodgkin’s lymphoma, tumors of epithelial cell origin, 
316 Zeng ZY, et al.   Sci China Life Sci   March (2014) Vol.57 No.3 
such as nasopharyngeal carcinoma (NPC) [15], and gastric 
cancer [6]. In tumor cells, EBV expresses a limited set of 
latent proteins, such as LMP1 [7], LMP2A [8], EBNA1–6, 
and a few non-coding RNAs (EBERs) [9]. EBV also ex-
presses 44 mature microRNAs (miRNAs) from 25 miRNA 
precursors encoded by two primary transcripts (BHRF1 and 
BART) [2,10]. 
miRNAs represent a conserved class of small noncoding 
RNAs that are found in all higher eukaryotes and some 
DNA viruses [1115]. These RNA molecules are 19–26 nt 
in length with partial homology to sequences in their target 
mRNAs [1620]. miRNAs bind to complementary mRNA 
sequences, reducing the stability of the target mRNAs. This 
binding impairs translation and inhibits the expression of 
target genes in a small interfering RNA (siRNA)-like man-
ner [1618]. miRNAs are involved in regulating a broad 
range of biological processes [19–25], such as signal trans-
duction pathways that are often dysregulated in cancers 
[2629].  
EBV miRNAs are expressed at various levels in tumor 
samples, including NPC, and different cell lines during viral 
latency and lytic growth [30,31]. The functions of EBV 
miRNAs in NPC are currently being explored by numerous 
researchers. Several genes involved in apoptosis, such as 
PUMA, BIM, and TOMM22, were identified as potential 
targets of various EBV miRNAs [32,33]. EBV BART 
miRNA targets, such as IPO7, Dicer, and LMP2A, partici-
pate in the immune evasion of NPC [31,34]. However, the 
biological effects and targets of EBV miRNAs have yet to 
be identified. 
In this study, we established a comprehensive EBV 
miRNA profile in NPC. Host target genes, the targetome, of 
these miRNAs were predicted and an EBV miRNA and 
gene regulation network was generated. Our findings 
demonstrate the potential role of viral miRNAs in control-
ling host gene expression and oncogenesis in NPC. 
1  Materials and methods 
1.1  Clinical samples and cell lines 
Ethics approval was obtained from the Ethics Review com-
mittees and the Institutional Review Boards of the Tumor 
Hospital and the Third Xiangya Hospital of the Central 
South University. NPC samples and non-tumor nasopha-
ryngeal epithelial tissues were collected, and written in-
formed consent was obtained from all patients. All 16 NPCs 
were non-keratinizing carcinoma (WHO II), according to 
WHO (1991) classification, including five samples for 
TNM stage II, five samples for stage III and six samples for 
stage IV. Five non-tumor nasopharyngeal epithelial tissues 
were obtained from patients with inflamed nasopharyngeal 
mucosa.  
Two EBV-negative (HK-1 and NP69) and three EBV- 
positive (Raji, C666-1, and B95-8) cell lines were grown in 
RPMI-1640 medium (Invitrogen, Breda, the Netherlands) 
supplemented with 10% fetal calf serum (FCS) (Gibco, 
Grand Island, NY, USA) and 1% penicillin/streptomycin 
(Invitrogen, Breda, the Netherlands). HEK293T cells were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM; 
Invitrogen) supplemented with 10% FCS (Gibco). 
1.2  RNA extraction and quantitative real-time PCR 
(qPCR) 
Total RNA was isolated using the RNeasy kit (Qiagen, Hil-
den, Germany) according to the manufacturer’s instructions. 
Expression levels of EBV miRNAs were measured by 
qPCR using the miScript system (Qiagen) according to the 
manufacturer’s instructions. The miRNAs were polyadenyl-
ated and then reverse-transcribed using oligo-dT primers 
that contain a universal tag at the 5′ end. A subsequent PCR 
step was then conducted using a primer specific for the 
universal tag and a primer specific for each miRNA (Qi-
agen). Accumulation of the PCR product was monitored 
using SYBR green dye (Bio-Rad, CA, USA).  
The cycle threshold (Ct) was defined as the number of 
PCR cycles required for a given reaction to reach an arbi-
trary fluorescence value within the linear amplification 
range. The change in Ct (∆Ct) was determined for each in-
dividual miRNA compared with the Ct for C666-1 cells, 
with the change in ∆Ct (∆∆Ct) determined by adjusting for 
the difference in a control reaction in which the RNU6B 
small nuclear RNA was amplified. The ∆∆Ct for each sam-
ple was transformed into relative expression level, and then 
normalized and visualized with Genesis software [35].  
To evaluate mRNA expression levels, qPCR assays were 
conducted using SYBR Premix Ex Taq™ (TaKaRa, Japan). 
We used the 2∆∆Ct to quantify mRNA transcripts, which 
were normalized to glyceraldehyde 3-phosphate dehydro-
genase (GAPDH). We used specific primers for GAPDH 
(5′-AAGGTGAAGGTCGGAGTCAAC-3′ and 5′-GGGTC- 
ATTGATGGCAACAATA-3′) and beta-transducin repeat 
containing E3 ubiquitin protein ligase (BTRC; 5′-GCTC- 
TATGCCCAGGTCTCTGT-3′ and 5′-GGGTTCGCCATT- 
ATTACAGTCTT-3′). 
1.3  In silico prediction of the EBV miRNA targetome 
in host cells 
The seed region sequences of all EBV miRNAs were indi-
vidually entered into TargetScan 4.1 (http://www.targetscan. 
org) [36] and RepTar (http://bioinformatics.ekmd.huji. 
ac.il/reptar) [37] to predict potential target genes for each 
miRNA. The overlapping potential target genes identified in 
both databases were retained for further analysis [38]. To 
determine the pathways shared by the target genes, the full 
list of predicted target genes was input into DAVID bioin-
formatics software (http://david.abcc.ncifcrf.gov) [39]. 
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1.4  Identification of dysregulated host genes in NPC 
Human gene expression profiles from 22 NPC biopsies and 
10 non-tumor nasopharyngeal epithelial tissues have been 
previously reported [40,41]. Genes that were significantly 
dysregulated in NPC biopsies compared with the non-tumor 
samples were identified using SAM 3.0 [42].  
1.5  Integrating analysis of EBV miRNA target genes 
and pathways 
Significantly downregulated genes in NPC and lists of pre-
dicted EBV miRNA target genes were compared to identify 
overlap between the two groups. Genes belonging to both 
the EBV miRNA target gene list and the list of genes sig-
nificantly downregulated in NPC were considered potential 
EBV miRNA target genes in NPC. EBV miRNAs and the 
potential target gene regulation network were analyzed and 
visualized using Pajek (http://pajek.imfm.si). 
1.6  EBV miRNA mimics, plasmids and transient 
transfection 
The syn-ebv-miR-BART10 miScript miRNA mimic was 
purchased from Qiagen. Allstars negative control (Qiagen) 
was used for miRNA transfection experiments.  
We synthesized two single strands encoding the 3′ un-
translated region (UTR) of the BTRC gene that contained 
the EBV-miR-BART10 binding site, and a mutant control, 
in which eight bases in the binding site were substituted. 
The oligonucleotides used in these studies were as follows: 
the 3′-UTR of BTRC, 5′-CTAGTCCAACCAGCACAGC-  
TGGCGCTCTTAGCTCCTGATTGGTTGTGTGTTTTAT- 
TAAA-3′ and 5′-AGCTTTTAATAAAACACACAACCA-  
ATCAGGAGCTAAGAGCGCCAGCTGTGCTGGTTGGA- 
3′; and the 3′-UTR of the mutant BTRC, 5′-CTAGTCC- 
AACCAGCACAGCTGGCGCTCTTAGCTCCTGATTAA- 
AGTACGGTTTTATTAAA-3′ and 5′-AGCTTTTAATAA- 
AACCGTACTTTAATCAGGAGCTAAGAGCGCCAGCT- 
GTGCTGGTTGGA-3′. The sense and antisense strands of 
the oligonucleotides were annealed, digested with Hind III 
and Spe I, and ligated into the pmiR-Report luciferase vec-
tor (Ambion, Austin, TX, USA). 
HEK293T cells were seeded in 24-well plates 24 h prior 
to transfection. The following day, 10 nmol L1 of 
syn-ebv-miR-BART10 miScript miRNA mimics along with 
200 ng of reporter plasmid or negative controls were 
co-transfected into cells using Lipofectamine 2000 (Invi-
trogen) according to the manufacturer’s recommendations. 
1.7  Western blotting 
Protein samples were separated by sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis and transferred onto 
nitrocellulose membranes as previously described [17]. The 
membranes were blocked with 5% non-fat milk and incu-
bated with the appropriate primary antibody followed by a 
horseradish peroxidase (HrP)-conjugated secondary anti-
body (Sigma, MO, USA). Primary antibody against BTRC 
was purchased from Cell Signaling (Danvers, MA, USA) 
and antibody against GAPDH was purchased from Sigma.  
1.8  Luciferase assays 
Luciferase activity was measured in cell lysates 24 h 
post-transfection using the Dual-Glo luciferase assay system 
(Promega, Madison, WI, USA) according to the manufac-
turer’s instructions. Renilla luciferase activity was used to 
normalize firefly luciferase activity. 
2  Results 
2.1  EBV miRNA profiles 
The expression levels of 44 mature EBV-encoded miRNAs 
and two latent protein genes (LMP1 and EBNA1) were de-
termined by qPCR in NPC tumor and non-tumor tissues, 
and in five cell lines. No EBV miRNAs or EBV latent pro-
tein genes were detected in the five non-tumor biopsies or in 
the two EBV-negative cell lines. Most of the 40 EBV 
miRNAs residing in the BART region and the latent protein 
genes were highly expressed in 14 of the 16 NPC samples 
and in the C666-1 cell line. Expression of these miRNAs 
was highest in stage III samples, and decreased in stage IV 
samples (Figure S1 in Supporting Information). No BHRF1 
miRNAs were detected in the nasopharyngeal epithelium, 
tumor tissues, or non-tumor tissues. In contrast, lymphoma 
cells derived from humans and marmosets (Raji and B95-8) 
exhibited high levels of BHRF1 miRNAs but low levels of 
BART miRNAs (Figure 1). 
2.2  Prediction of target genes and pathways for EBV 
miRNAs 
TargetScan and RepTar were used to predict target genes. 
Because the EBV-encoded BHRF1 miRNA cluster was not 
expressed in NPC, only the BART miRNA cluster was con-
sidered for further analysis. The 40 mature BART miRNA 
sequences were obtained from miRBase and input into Tar-
getScan and RepTar to generate two separate lists of pre-
dicted target genes. Using TargetScan, 5569 target genes 
were predicted, and RepTar predicted 6494 genes. A total of 
3140 genes were identified by both bioinformatics tools. 
Among these 3140 genes, BART18-5p had the highest 
number of targets (148 genes), whereas BART8, BART13*, 
and BART19-3p had no potential target host genes. 
To determine which pathways were commonly targeted 
by BART miRNAs, the 3140 target genes were subjected to 
functional clustering analysis using DAVID. The results 
showed that BART miRNAs target a wide range of path-  
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Figure 1  Heatmap of EBV-encoded miRNAs in biopsies and cell lines. The gene expression profile of the 44 EBV-encoded mature miRNAs and the two 
mRNAs encoding LMP-1 and EBNA1 in five non-tumor nasopharyngeal epithelium tissues (N, EBV negative), five clinical stage II NPC biopsies (II), five 
stage III NPC biopsies (III), five stage IV NPC biopsies (IV), two EBV-negative nasopharyngeal epithelium cell lines named NP69 (immortalized normal 
nasopharyngeal epithelium) and HK1 (NPC) and three EBV-positive cell lines named C666-1 (NPC), Raji (Burkitt’s lymphoma) and B95-8 (marmoset 
B-cell), were detected by qPCR and then normalized and visualized by Genesis software. Red represents high expression and green represents low or absent 
expression. Note that the first stage II NPC biopsy and the last NPC stage IV biopsy were EBV negative. 
ways, with the five most significant pathways listed in Ta- 
ble 1. These include axon guidance, cancer pathways, the 
WNT signaling pathway, regulation of the actin cytoskele-
ton, and adherens functions.  
2.3  Integrated analysis of the EBV targetome and the 
NPC transcriptome 
The SAM test was used to compare the transcriptomes of 
NPC and non-tumor tissues. We found that 732 genes were 
significantly dysregulated in NPC, including 270 upregu-
lated and 462 downregulated genes (Figure 2). The 462 
downregulated genes were compared with the 3140 poten-
tial EBV miRNA target genes. We found that 105 genes 
were both downregulated in NPC and predicted as potential 
targets of EBV miRNAs by TargetScan and RepTar (Fig- 
ure 3). 
2.4  EBV miRNA and target gene regulation network 
For the 105 genes that were downregulated in NPC and tar-
geted by EBV miRNAs, 175 miRNA:mRNA target pairs 
were identified. BART22 had the highest number of    
potential targets (37 genes), followed by BART8* (23), 
BART18-5p (12), BART9 (11), and BART14 (11). These 
five EBV miRNAs regulated 94 of the 175 (53.4%) miR-
NA:mRNA target pairs (Table 2). Certain genes, such as 
ATRX, BTRC, CTBP2, FOXP1, and NFIB, were predicted to 
have several EBV miRNA binding sites in their 3′-UTRs 
(Table 3). To illustrate the complexity of the regulatory re-
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Table 1  The five top targeted EBV miRNA pathways in host cells 
KEGG pathway Count P-value 
Axon guidance 53 1.30×10 
Pathways in cancer 98 2.30×10 
Wnt signaling pathway 53 7.80×10 
Regulation of actin cytoskeleton 67 2.20×10 
Adherens function 32 7.80×10 
Table 2  The five EBV miRNAs with the highest number of target genes 
miRNA Genes 
BART22 ADCY2, ATP9A, ATRX, C2orf24, CALM1, CD47, CP, CTBP2, CTSS, EPAS1, F11R, FAM8A1, FOXP1, INSR, IPO11,
KIAA0895, KIF21A, KLHL5, MCRS1, MLL5, NEBL, NFIA, NFIB, NPAS2, OSBPL10, PCDHA5, PCM1, PHF17, PLD2,
PPP2R5A, SFRS5, SORT1, SYTL2, TMF1, TOB2, TUSC2, UBE2J1 
BART8* ABCE1, ARHGAP5, ASXL2, ATRX, C9orf5, CLASP2, CRY2, CTBP2, CTNNB1, DNER, GFPT1, IL1RN, KIAA0895, KPNA3,
MAP6, NFIB, OXTR, PCM1, PFN2, PLCB4, STK39, TLE4, TRIB2 
BART18-5p BTRC, C9orf5, CLASP2, EAF1, EPAS1, KIAA0895, KIF3B, KLHL2, MAP1A, NUCB2, STK39, TNFRSF21 
BART9 CLASP2, DAG1, EPAS1, EPHA2, FAM8A1, LACTB, MCOLN3, MYRIP, NFIA, NFIB, SLC39A9 
BART14 ABCE1, ALDH1A2, ATRX, CENTD1, EFHC1, FOXP1, NFIB, PPP2R5A, SLC16A2, TUSC2, UBP1 
Table 3  The five most likely host genes targeted by EBV miRNAs 
Gene miRNAs 
ATRX BART4*, BART8*, BART14, BART20-5p, BART22 
BTRC BART4, BART4*, BART6-3p, BART10, BART18-5p, BART19-5p 
CTBP2 BART8*, BART10*, BART13, BART22 
FOXP1 BART11-5p, BART11-3p, BART12, BART14, BART15, BART17-5p, BART19-5p, BART22 
NFIB BART8*, BART9, BART9*, BART10, BART14, BART22 
 
 
Figure 2  The heatmap of 462 down-regulated host genes in NPC and non-tumor tissues. The SAM test was applied to compare the whole-genome wide 
mRNA expression profile of NPC (n=27) and nasopharyngeal epithelium tissues (n=10). 732 genes were significantly dysregulated in NPC, including 270 
up-regulated genes and 462 down-regulated genes. 462 down-regulated genes’ expression profile were normalized and visualized by Genesis software. Red 
represents high expression and green represents low or absent expression. 
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Figure 3  Venn diagram of the EBV miRNA target genes predicted using 
two types of software and the significantly down-regulated genes in NPC 
identified using SAM analysis. Forty mature BART miRNA sequences 
were obtained from miRBase and input onto TargetScan and RepTar to 
predict their target genes. A total of 6494 human target genes were pre-
dicted by RepTar (A), and 5569 genes were predicted by TargetScan (B). 
A total of 3140 genes were identified by both bioinformatic tools (D). To 
integrate the analysis of the EBV targetome and transcriptome of NPC, 462 
down-regulated genes in NPC that were found using SAM 3.0 from the 
whole genome gene expression profile data of 10 non-tumor nasopharyn-
geal epithelia and 22 NPC (C) were compared to the EBV miRNA target 
gene list. A total of 105 genes that are down-regulated in NPC were also 
predicted as potential targets of EBV miRNAs by both TargetScan and 
RepTar (G). 
lationships between EBV miRNAs and host genes, their 
regulatory network was visualized using Pajek (Figure 4). 
2.5  Low expression of BTRC and negative correlation 
with EBV-miR-BART10 
Expression of BTRC was significantly low in the mRNA  
expression profiles of NPC biopsies (Figure 5A). To date, 
there have been no reports of a mechanistic link between the 
BTRC gene and NPC tumorigenesis. Using qPCR assays, 
we measured the expression of BTRC and EBV-miR- 
BART10 in another group of clinical biopsies. Our qPCR 
results verified that BTRC was significantly downregulated 
in NPC samples (Figure 5B), while EBV-miR-BART10 was 
upregulated (Figure 5C) and negatively correlated with 
BTRC gene expression (Figure 5D). 
2.6  EBV-miR-BART10 downregulated BTRC expres-
sion 
To determine whether BTRC is an authentic EBV-miR- 
BART10 target, we transiently expressed EBV-miR- 
BART10 mimics in HEK293T cells (Figure 6A). After 24 h, 
EBV-miR-BART10 mimics significantly reduced expres-
sion of endogenous BTRC mRNA (Figure 6B). Similarly, 
expression of BTRC protein level was also decreased (Fig-
ure 6C). These results confirmed that EBV-miR-BART10 
modulated expression of the BTRC gene. 
2.7  EBV-miR-BART10 targets the 3′-UTR of the 
BTRC gene 
TargetScan, RepTar, miRanda and RNAhybrid all predicted 
six EBV-miR-BART10 binding sites in the 3′-UTR of 
BTRC. The predicted binding site was around nt 3751 of the 
BTRC 3′-UTR, had the lowest MFE (25.7 kcal mol1)  
and exhibited the best complementarity to EBV-miR- 
BART10 (Figure 7A). To validate the recognition of this  
 
 
Figure 4  Potential regulating network of EBV miRNAs and their host cellular target genes. The red circles represent EBV-encoded miRNAs, and the green 
squares represent host target genes; the size of each shape represents the number of regulating relationships. 
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Figure 5  The expression of EBV miR-BART10 and BTRC in NPC samples. A, The normalized expression of BTRC in our previous reported gene expres-
sion profile data of NPC and normal nasopharynx epithelia tissues. B, Real-time PCR results of BTRC expression in another group of clinical biopsies veri-
fied that BTCR was significantly down-regulated in NPC samples. C, Real-time PCR measured the EBV miRNA BART10 expression in the same samples 
of Figure 5B, and found that BART10 was significantly up-regulated in NPC biopsies. D, We compared the BTRC and BART10 expression data in Figure 
5B and C, and found that BART10 and BTRC expression was negatively correlated. 
 
Figure 6  EBV miRNA BART10 down-regulated BTRC expression. A, EBV miRNA BART10 mimics was transfected in HEK 293T cells, allstars nega-
tive control (NC) was used. After 24 h, BART10 expression level was confirmed by real-time PCR, the expression of RNU6B small nuclear RNA was meas-
ured and used for data normalization. **, P<0.01. B, Real-time PCR analysis of BTRC mRNA expression in HEK293T cells transfected with EBV miRNA 
BART10 or negative control (NC) mimics, GAPDH was selected as a control. BART10 mimics significantly down-regulated the endogenous BTRC mRNA 
expression. *, P<0.05. C, Western blotting analysis of BTRC protein expression in HEK293T cells transfected with EBV miRNA BART10 or negative con-
trol (NC) mimics, GAPDH was selected as a control. BART10 mimics significantly down-regulated the endogenous BTRC protein expression. 
site by EBV-miR-BART10, luciferase assays were con-
ducted. The target site in the BTRC 3′-UTR and a mutant 
control were synthesized and cloned into a pmiR-Report 
luciferase vector (Figure 7B). The pmiR-report constructs 
were co-transfected into HEK293T cells with 10 nmol L1 
EBV-miR-BART10 mimics or all-star negative control for 
24 h. Co-transfection with EBV-miR-BART10 mimics re-
sulted in a significant reduction of luciferase activity. No 
inhibition was observed when the BTRC 3′-UTR binding 
site was mutated (Figure 7C).  
3  Discussion 
The risk factors for NPC include both environmental and 
genetic factors. However, how these risk factors interact is 
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Figure 7  EBV miRNA BART10 target to the 3′-UTR of BTRC mRNA. A, There are six EBV miRNA BART10 binding sites located within the 3′-UTR of 
human BTRC mRNA. The positions and their minimal free energy (MFE, kcal mol1) of the EBV miRNA BART10 target sites located within the BTRC 
3′-UTR are schematically presented. The predicted binding site around the 3751 bp of the BTRC 3′-UTR has the lowest MFE (25.7 kcal mol1) and exhibits 
the best complementarity to miRNA BART10. B, The binding site of EBV miR-BART10 in BTRC 3′-UTR around 3751 bp was mutated by replacing eight 
bases in the seed sequence. Synthesized oligonucleotides containing wild type or mutated BART10 binding site were inserted into the luciferase report plas-
mids. C, HEK293T cells were co-transfected with 10 nmol L1 EBV miR-BART10 mimics or allstar negative control, and 200 ng pmiR-Report-BTRC 
3′-UTR, pmiR-Reporter-BTRC 3′-UTR mutant or empty pmiR-Report vector (as control) plasmids. EBV miR-BART10 significantly down-regulates BTRC 
3′-UTR reporter activity in HEK293T cells. *, P< 0.05. 
not well understood [4349]. EBV is a typical environmen-
tal oncogenic virus of NPC that can transform cells and 
subsequently induce cell proliferation and tumor growth. 
The identification of virus-encoded miRNAs and their host 
target genes provides an ideal model for investigating the 
interaction between environmental and genetic risk factors 
in NPC, and will potentially generate new insights into viral 
transformation. Previous studies identified 44 miRNAs in 
the EBV genome [10]. Detailed characterization of the 
miRNA profiles in NPC will help elucidate the contribution 
of these miRNAs to cancer pathogenesis. Expression of 
EBV-encoded miRNAs in NPC and other EBV-positive 
cells were profiled using qPCR assays, and the results 
showed that NPC and lymphoma cells have distinct EBV 
miRNA expression profiles, and that all miRNAs from the 
BART cluster are expressed in NPC tissues. BHRF1 miR-
NAs are highly expressed in lymphoma cells, while BART 
miRNA expression is low or absent, suggesting that the 
BHRF1 and BART clusters of EBV miRNAs possibly play 
different roles and function via different mechanisms to 
transform cancers derived from epithelial or B-cell lineages 
[50]. The expression of BART miRNAs was highest in 
clinical stage III samples, with levels in stage IV samples 
somewhat lower. These findings support the “hit-and-run” 
viral oncogenesis hypothesis [51,52]. 
Determination of how EBV-encoded miRNAs control 
the expression of host genes and the elucidation of molecu-
lar mechanisms for EBV miRNAs in NPC carcinogenesis 
requires comprehensive identification of all host target 
genes for these miRNAs. Identifying this targetome has 
been a very difficult task. To enhance the accuracy of 
miRNA target prediction, TargetScan and RepTar were 
used in this study. Only genes predicted by both programs 
were included in the target gene pool, which resulted in a 
targetome of 3140 potential genes. DAVID analysis sug-
gested that many cytoskeletal and adherens-related genes 
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were regulated by EBV miRNAs, implying that EBV 
miRNAs most likely regulate the invasion and metastasis of 
tumors. Consistent with other studies, the WNT signaling 
pathway [4,53] was also identified as an important down-
stream cascade regulated by EBV miRNAs [54]. 
Because the predicted EBV miRNA target genes might 
not be expressed in NPC, transcriptome data was analyzed 
for identification of downregulated genes and compared 
with the predicted EBV miRNA targetome. A total of 105 
genes were predicted to contain EBV miRNA target sites in 
their 3′-UTR, with expression patterns negatively correlated 
with those of EBV miRNAs. These 105 genes are the most 
likely EBV miRNA-regulated host genes in NPC develop-
ment.  
The relationship between host genes and EBV miRNAs 
is complex. The 105 genes identified are potentially target-
ed by 28 EBV miRNAs. Some miRNAs, such as BART22, 
BART8*, and BART18-5p, may target multiple genes, 
while some genes may be targeted by several miRNAs. In 
total, 175 miRNA:mRNA target pairs were identified. 
These results imply that synchronous and synergistic ex-
pression and regulation of EBV miRNAs and host genes 
may cooperate to transform nasopharyngeal epithelium cells. 
Among the five host genes with the largest number of bind-
ing sites for EBV-encoded miRNAs, BTRC and alpha tha-
lassemia/mental retardation syndrome X-linked (ATRX) are 
tightly associated with viral infection. 
The BTRC gene encodes the β-TrCP1 F-box protein, 
which is an E3 ubiquitin protein ligase that targets various 
substrates such as β-catenin, IBα, ATF4, CDC25A, CD4, 
and Snail [5561]. β-TrCP1 is essential for many aspects of 
tumorigenesis [62,63]. β-TrCP1 interacts with HIV-1 Vpu 
and regulates HIV release by mediating the degradation of 
its substrates. Additionally, Tang et al. found that the EBV 
LMP1-95-8 variant reduced the levels of endogenous 
β-TrCP2/HOS via phosphorylated IBα, suggesting that 
LMP1-95-8 is a pseudo-substrate of the SCFβ-TrCP/HOS 
E3 ubiquitin ligase and that interaction between LMP1 and 
HOS restricts the extent of LMP1-induced NF-B signaling 
[64]. 
ATRX is a component of the PML nuclear body 
(PML-NB), which is the nuclear localization site of many 
DNA viruses, including herpes simplex virus 1 (HSV-1), 
human cytomegalovirus and adenovirus 5 [65]. ATRX is 
also associated with herpesvirus infections. Upon entering 
the host cell nucleus, the herpesvirus genome must deal 
with intrinsic antiviral resistance that restricts viral gene 
expression and replication. The EBV major tegument pro-
tein, BNRF1, interacts with the host nuclear protein Daxx in 
PML-NBs and disrupts the formation of the Daxx-ATRX 
chromatin remodeling complex. This would indicate that 
ATRX plays a role in the regulation of early EBV infection 
[66]. Jurak et al. [67] found that ATRX is a target of HSV-1 
miR-H1 and HSV-2 miR-H6, suggesting that ATRX may 
repress lytic viral gene expression through its miRNAs.  
In this study, we selected the EBV-miR-BART10:BTRC 
target pair for experimental manipulation. We found that 
EBV-miR-BART10 could efficiently repress BTRC expres-
sion levels, and that this was dependent on the BTRC 
3′-UTR. The reduction of BTRC by EBV-miR-BART10 
possibly results in decreasing degradation of its substrates, 
including IκBα and β-catenin, ATF4, CDC25A, CD4, and 
Snail [5661]. This could regulate the development of NPC. 
Elucidating the function of this miRNA should assist in 
identifying new mechanisms by which EBV infection leads 
to transformation and malignancy. 
This report provides the first EBV miRNA and host 
mRNA regulation network. Our results provide a starting 
point for systematically identifying and clarifying the essen-
tial miRNAs encoded by EBV and the regulated signaling 
pathways for these miRNAs during NPC development. In-
terfering with overexpressed miRNAs or the artificial ex-
pression of the mRNAs downregulated by these miRNAs 
might be useful for NPC therapy in the future [6873]. We 
postulate that these miRNAs, or mRNAs, most likely act as 
biomarkers for NPC diagnosis or prognosis. 
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Figure S1  All of 40 EBV encoded BART cluster miRNAs expression profiling in different clinical stages of NPC samples and normal tissues. N, Normal; 
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